Prescription Orthopedic Drugs Market Report 2026

Prescription Orthopedic Drugs Market Overview

• Prescription Orthopedic Drugs market size has reached to $51.06 billion in 2025 • Expected to grow to $67.5 billion in 2030 at a compound annual growth rate (CAGR) of 5.7% • Growth Driver: Rising Prevalence Of Musculoskeletal Disorders Driving Demand For Treatment Solutions • Market Trend: Advancements In Orthopedic Drug Indications For Enhanced Surgical Pain Management • North America was the largest region in 2025.

What Is Covered Under Prescription Orthopedic Drugs Market?

Prescription orthopedic drugs refer to medications specifically prescribed to manage conditions affecting the musculoskeletal system, such as bones, joints, muscles, and ligaments. They are used for pain relief, inflammation reduction, and promoting healing in orthopedic injuries or disorders like arthritis, fractures, and tendonitis. The main drug types of prescription orthopedic drugs are nonsteroidal anti-inflammatory drugs (NSAIDs), opioids, corticosteroids, disease-modifying antirheumatic drugs (DMARDs), and others. Nonsteroidal anti-inflammatory drugs (NSAIDs) are a class of medications that reduce pain, inflammation, and fever by inhibiting enzymes involved in the production of prostaglandins. These drugs are used for conditions such as osteoarthritis, rheumatoid arthritis, osteoporosis, and other related disorders. They are distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies.

What Is The Prescription Orthopedic Drugs Market Growth Forecast?

The prescription orthopedic drugs market size is expected to see strong growth in the next few years. It will grow to $67.5 billion in 2030 at a compound annual growth rate (CAGR) of 5.7%. The growth in the forecast period can be attributed to rising osteoarthritis cases, growing demand for long-term pain control, expansion of biologic orthopedic drugs, increased sports injury incidence, rising orthopedic drug prescriptions. Major trends in the forecast period include rising demand for pain management therapies, increased use of anti-inflammatory orthopedic drugs, growing focus on chronic joint disorder treatment, expansion of dmard usage in orthopedics, increased adoption of combination pain therapies.

What Is The Driver Of The Prescription Orthopedic Drugs Market?

The increasing incidence of musculoskeletal disorders is expected to drive the growth of the prescription orthopedic drugs market going forward. Musculoskeletal disorders (MSDs) are injuries and conditions that affect the movement and function of the human body's musculoskeletal system, which includes muscles, tendons, ligaments, nerves, and joints, resulting in pain and reduced mobility. The increasing incidence of musculoskeletal disorders is primarily due to factors such as aging, occupational activities involving repetitive movements and awkward postures, lifestyle choices such as physical inactivity and poor nutrition, and genetic predispositions. Prescription orthopedic drugs play a vital role in managing musculoskeletal disorders by alleviating pain, reducing inflammation, and enhancing the healing process, thereby improving mobility and overall quality of life. For instance, in March 2023, according to the Office for Health Improvement & Disparities (UK), the prevalence of long-term self-reported musculoskeletal (MSK) conditions in people aged 16 and over rose to 17.6% in 2022. Therefore, the increasing incidence of musculoskeletal disorders is driving the growth of the prescription orthopedic drugs industry.

Key Players In The Global Prescription Orthopedic Drugs Market

Major companies operating in the prescription orthopedic drugs market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck KGaA, AbbVie Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca plc, GSK plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Biogen Inc., UCB S.A., Allergan plc, Horizon Therapeutics plc, Sun Pharmaceutical Industries Ltd.

Global Prescription Orthopedic Drugs Market Trends and Insights

Major companies operating in the prescription orthopedic drugs market are focusing on expanding indications for their drugs to broaden, such as extended-indication analgesic formulation to enhance postoperative pain management across a broader range of orthopedic and soft-tissue procedures. Extended-indication analgesic formulation refers to a pain-relief drug whose approved clinical use has been broadened to cover additional medical procedures, conditions, or patient groups beyond its original authorization. For instance, in January 2023, Heron Therapeutics Inc., a US-based biotechnology company, received FDA approval for the expanded use of ZYNRELEF (bupivacaine and meloxicam) in soft tissue and orthopedic procedures, including foot and ankle surgeries. This extended-release solution is uniquely designed to provide prolonged pain relief for up to 72 hours, reducing or eliminating the need for opioids after surgery. The expanded indication now covers additional orthopedic and soft tissue procedures, including foot and ankle surgeries, broadening its applicability in clinical settings. Its innovative dual-drug combination delivers both local anesthetic and anti-inflammatory effects, making it a comprehensive option for managing post-operative pain with enhanced patient outcomes.

What Are Latest Mergers And Acquisitions In The Prescription Orthopedic Drugs Market?

In April 2024, ProMed Pharma LLC, a US-based pharmaceutical company, acquired SpineThera Inc. for an undisclosed amount. With this acquisition, ProMed aims to enhance its drug delivery capabilities by leveraging SpineThera’s expertise in extended-release injectable therapies, particularly for pain management in musculoskeletal and orthopedic conditions. SpineThera Inc. is a US-based company that specializes in extended-release injectable therapies for pain management in musculoskeletal conditions, including back pain and orthopedic disorders.

What Defines the Prescription Orthopedic Drugs Market?

The prescription orthopedic drugs market consists of sales of products such as bisphosphonates, creams, gels, or patches, calcium and vitamin D supplements, and analgesics. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Prescription Orthopedic Drugs Market Report 2026?

The prescription orthopedic drugs market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the prescription orthopedic drugs industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.